At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 986 enrolled
Drug / intervention
Insulin Efsitora Alfa +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3, Multicenter, Randomized, Parallel-Design, Open-Label Trial to Evaluate the Efficacy and Safety of LY3209590 Compared With Insulin Degludec in Participants With Type 2 Diabetes Currently Treated With Basal Insulin (QWINT-3)
In Brief
A Phase 3 clinical trial evaluating Insulin Efsitora Alfa and Insulin Degludec for Type 2 Diabetes. Completed, enrolled 986 participants across 127 sites in 10 countries.
Detailed Summary
The reason for this study is to see if the study drug insulin efsitora alfa (LY3209590) is safe and effective in participants with Type 2 diabetes that have already been treated with basal insulin. The study consists of a 3-week screening/lead-in period, a 78-week treatment period and a 5-week safety follow-up period. The study will last up to 86 weeks.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType 2 Diabetes
CountriesArgentina, Hungary, Japan, Poland, Puerto Rico, Slovakia, South Korea, Spain, Taiwan, United States
Collaborators--
Timeline
Phase 3CompletedFinished
2023202420252026
Enrollment StartMar 2022
First PostedMar 2022
Primary CompletionMay 2024
TodayJul 2026
First PostedMar 11, 2022
Enrollment StartMar 8, 2022
Primary CompletionMay 15, 2024
TodayJul 2, 2026
Enrollment to primary: 2.2 yearsPosted 4.3 years ago
Interventions
Insulin Efsitora Alfadrug
Administered SC
Insulin Degludecdrug
Administered SC